Transdermal drug delivery systems specialist Aveva Drug Delivery Systems, a DifGen company, announced on Monday the launch of all strengths of its generic Fentanyl Transdermal Patch in the United States.

A generic equivalent to Duragesic, Fentanyl TDS is a prescription 3-day transdermal patch for managing moderate to severe chronic pain. The US launch required the rapid sourcing and seamless integration of advanced manufacturing equipment with existing systems to meet regulatory and operational standards.

Ramandeep Singh Jaj, DifGen Pharmaceuticals founder and co-CEO, said: "Chronic pain significantly impacts quality of life. Our goal is to provide patients and healthcare providers with effective, reliable options for this essential pain management product, that can eliminate consistent supply disruptions leading to cyclical shortages that can place undue burden on the US healthcare system."